A Phase II Evaluation of AMG 102 (Rilotumumab) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

PURPOSE: This open-label, multi-institutional Phase II trial evaluated activity and safety of rilotumumab (AMG 102), a monoclonal antibody that targets HGF (hepatocyte growth factor), the ligand for the MET receptor, in women with recurrent or persistent epithelial ovarian, fallopian tube or primary...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Martin, Lainie P., Sill, Michael, Shahin, Mark S., Powell, Matthew, DiSilvestro, Paul, Landrum, Lisa M., Gaillard, Stephanie L., Goodheart, Michael J., Hoffman, James, Schilder, Russell J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4469031/
https://ncbi.nlm.nih.gov/pubmed/24361733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.12.018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados